<DOC>
	<DOC>NCT01820715</DOC>
	<brief_summary>A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.</brief_summary>
	<brief_title>A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>20≤ Age ≤ 70 Diagnosed with Type I or Type II diabetes HbA1c ≤ 11% Patients with diabetic neuropathic pain for at least 3 months Patients corresponding to average pain level of 4 points or mor for 24 hours evaluated with 11point Likert scale Neuropathic pain due to other causes Another stronger pain other than neuropathic pain Abnormality in blood pressure, weight Positive reaction in HIV, HBV or HCV A medical history of mental illness within 6 months The grade of BDI(Beck Depression Inventory) exceeds 21 points History of drug/alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>